Fred D. Lublin, MD

Host Jeffrey Wilken, PhD, chats with Fred Lublin, MD; Brian Hutchinson, PT, MSCS; and Robert Motl, PhD, about the second day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

Key opinion leaders in multiple sclerosis (MS) discuss the future of relapsing MS management and unmet needs.

Expert neurologists discuss current and future biomarkers relevant to relapsing multiple sclerosis including cerebrospinal fluid neurofilament.

The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke on what he is looking forward to at the 2021 International Congress on the Future of Neurology.

A panel of experts emphasize the importance of shared decision making in relapsing multiple sclerosis and discuss lifestyle choices that impact the disease.

Experts in multiple sclerosis (MS) discuss key factors involved in the sequencing of therapies for relapsing MS.

Lauren Gluck, MD discusses considerations for monitoring response to treatment in relapsing multiple sclerosis.

Lauren Gluck, MD, and Ravi Dukkipati, MD, provide an overview of teriflunomide for relapsing multiple sclerosis including its safety and tolerability profile.

Experts in the field of multiple sclerosis provide insight into the fumarates as a viable oral option for relapsing MS.  

A panel of experts discuss the use of anti-CD20 monoclonal antibodies in relapsing multiple sclerosis including summaries of the phase III ORATORIO and ASCLEPIOS trials, for ocrelizumab and ofatumumab, respectively.

Expert neurologists discuss the role of sphingosine-1-phosphate (S1P) receptor modulators in relapsing multiple sclerosis including vaccine considerations and pediatric use.

Key opinion leaders provide insight into the use cladribine for relapsing multiple sclerosis including durability and safety profile.

Gavin Giovannoni, MD provides an overview of the development and pharmacodynamics of cladribine in multiple sclerosis.

Fred D. Lublin, MD, Ravi Dukkipati, MD, and Lauren Gluck, MD, discuss interferons and glatiramer as platform therapies in multiple sclerosis.

Experts in multiple sclerosis (MS) provide an overview of treatment strategies and selection in relapsing MS.

Fred D. Lublin, MD discusses the diagnosis of multiple sclerosis and the 2017 revisions of the McDonald criteria.  

Joseph R. Berger, MD, and Fred D. Lublin, MD, offer advice to community physicians and neurologists in managing patients with multiple sclerosis.

Kristen Krysko, MD, and Robert Fox, MD, look to the future of multiple sclerosis management. 

Considerations regarding the role of exercise and combatting fatigue when treating patients with multiple sclerosis.

The importance of proper nutrition as a therapy for symptom control in multiple sclerosis and some strategies to manage cognitive impairment. 

Joseph R. Berger, MD, elaborates on the importance of shared decision making in the treatment of multiple sclerosis and how it relates to complementary and natural therapies for symptom control.

Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.

Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.

Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.

A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.

Experts in the field of multiple sclerosis discuss patient selection for drugs based on disease activity.

Kristen Krysko, MD, summarizes the results of the phase III ORATORIO trial and discusses the rationale for using ocrelizumab for the treatment of progressive multiple sclerosis.  

Experts in the field of multiple sclerosis compare the results of the EXPAND study to the results of the ASCEND study.

Robert Fox, MD, discusses the rationale for using siponimod for the treatment of progressive multiple sclerosis as well as the practical implications of the phase 3 EXPAND trial.

A comparison of various factors considered when treating primary progressive multiple sclerosis versus secondary progressive multiple sclerosis.